Morphic Holding Dirección
Dirección controles de criterios 3/4
El CEO de Morphic Holding's es Bruce Rogers , nombrado en May 2022, tiene una permanencia de 1.92 años. compensación anual total es $5.26M, compuesta por 9.6% salario y 90.4% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.3% de las acciones de la empresa, por valor de $4.27M. La antigüedad media del equipo directivo y de la junta directiva es de 2 años y 6.8 años, respectivamente.
Información clave
Praveen Tipirneni
Chief Executive Officer (CEO)
US$8.9m
Compensación total
| Porcentaje del salario del CEO | 6.9% |
| Permanencia del CEO | 8.8yrs |
| Participación del CEO | 1.3% |
| Permanencia media de la dirección | 3.1yrs |
| Promedio de permanencia en la Junta Directiva | 6.9yrs |
Actualizaciones recientes de la dirección
Recent updates
We're Hopeful That Morphic Holding (NASDAQ:MORF) Will Use Its Cash Wisely
Jan 20
Companies Like Morphic Holding (NASDAQ:MORF) Are In A Position To Invest In Growth
Sep 29We're Interested To See How Morphic Holding (NASDAQ:MORF) Uses Its Cash Hoard To Grow
Jun 07What Does The Future Hold For Morphic Holding, Inc. (NASDAQ:MORF)? These Analysts Have Been Cutting Their Estimates
Feb 15We're Hopeful That Morphic Holding (NASDAQ:MORF) Will Use Its Cash Wisely
Jan 03What Does The Future Hold For Morphic Holding, Inc. (NASDAQ:MORF)? These Analysts Have Been Cutting Their Estimates
Nov 08Morphic GAAP EPS of -$0.68 beats by $0.17, revenue of $60.2M
Aug 03Revenue Downgrade: Here's What Analysts Forecast For Morphic Holding, Inc. (NASDAQ:MORF)
May 06Analyst Forecasts Just Became More Bearish On Morphic Holding, Inc. (NASDAQ:MORF)
Mar 01Here's Why We're Not Too Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn Situation
Feb 17We're Not Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn
Nov 03Morphic: Pioneering Integrin Medicines
Oct 13Morphic Holding (NASDAQ:MORF) Is In A Strong Position To Grow Its Business
Aug 05Companies Like Morphic Holding (NASDAQ:MORF) Can Afford To Invest In Growth
Apr 05Independent Director Vikas Goyal Just Bought A Handful Of Shares In Morphic Holding, Inc. (NASDAQ:MORF)
Mar 09Did Business Growth Power Morphic Holding's (NASDAQ:MORF) Share Price Gain of 126%?
Feb 24How Many Morphic Holding, Inc. (NASDAQ:MORF) Shares Have Insiders Sold, In The Last Year?
Jan 20Morphic Holding (MORF) Presents At 39th Annual Healthcare Conference - Slideshow
Jan 14Companies Like Morphic Holding (NASDAQ:MORF) Can Afford To Invest In Growth
Dec 16Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$161m |
| Dec 31 2023 | US$9m | US$614k | -US$152m |
| Sep 30 2023 | n/a | n/a | -US$136m |
| Jun 30 2023 | n/a | n/a | -US$130m |
| Mar 31 2023 | n/a | n/a | -US$64m |
| Dec 31 2022 | US$11m | US$602k | -US$59m |
| Sep 30 2022 | n/a | n/a | -US$56m |
| Jun 30 2022 | n/a | n/a | -US$51m |
| Mar 31 2022 | n/a | n/a | -US$106m |
| Dec 31 2021 | US$5m | US$579k | -US$96m |
| Sep 30 2021 | n/a | n/a | -US$92m |
| Jun 30 2021 | n/a | n/a | -US$61m |
| Mar 31 2021 | n/a | n/a | -US$50m |
| Dec 31 2020 | US$4m | US$559k | -US$45m |
| Sep 30 2020 | n/a | n/a | -US$47m |
| Jun 30 2020 | n/a | n/a | -US$61m |
| Mar 31 2020 | n/a | n/a | -US$55m |
| Dec 31 2019 | US$788k | US$498k | -US$43m |
| Sep 30 2019 | n/a | n/a | -US$29m |
| Jun 30 2019 | n/a | n/a | -US$27m |
| Mar 31 2019 | n/a | n/a | -US$24m |
| Dec 31 2018 | US$2m | US$402k | -US$24m |
Compensación vs. Mercado: La compensación total de Praveen($USD8.91M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD5.66M).
Compensación vs. Ingresos: La compensación de Praveen ha sido consistente con los resultados de la empresa en el último año.
CEO
Praveen Tipirneni (55 yo)
8.8yrs
Permanencia
US$8,907,684
Compensación
Dr. Praveen P. Tipirneni, M.D., has been a Director at Tectonic Therapeutic, Inc. He serves as an Independent Director at Panacea Acquisition Corp. II since April 6, 2021. He serves as Chief Executive Offi...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, MD & Director | 8.8yrs | US$8.91m | 1.31% $ 20.2m | |
| President | 2yrs | US$4.88m | 0.30% $ 4.6m | |
| Founder | 9.8yrs | US$539.99k | 15.24% $ 235.1m | |
| CFO & COO | 4.1yrs | US$4.65m | 0.076% $ 1.2m | |
| Senior VP of Finance & Chief Accounting Officer | 4.3yrs | US$4.03m | 0.070% $ 1.1m | |
| Chief Scientific Officer | 2yrs | sin datos | sin datos | |
| General Counsel & Secretary | 5.3yrs | US$2.24m | 0.046% $ 709.3k | |
| Senior Vice President of Business & Corporate Development | 2.1yrs | sin datos | sin datos | |
| Senior Vice President of Regulatory Affairs | 2yrs | sin datos | sin datos | |
| Chief Medical Officer | less than a year | sin datos | sin datos |
3.1yrs
Permanencia media
54yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de MORF se considera experimentado (3 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, MD & Director | 8.8yrs | US$8.91m | 1.31% $ 20.2m | |
| Founder | 8.9yrs | US$539.99k | 15.24% $ 235.1m | |
| Independent Director | 4.9yrs | US$545.74k | 0% $ 0 | |
| Independent Director | 5yrs | US$560.74k | 0.018% $ 279.3k | |
| Independent Director | 3.4yrs | US$547.49k | 0.0047% $ 73.1k | |
| Independent Chairman | 8.3yrs | US$586.49k | 0.20% $ 3.1m | |
| Independent Director | 6.9yrs | US$544.99k | 0.00029% $ 4.5k | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos |
6.9yrs
Permanencia media
62yo
Promedio de edad
Junta con experiencia: La junta directiva de MORF se considera experimentada (6.8 años de antigüedad promedio).